Michael Charlton to End Stage Liver Disease
This is a "connection" page, showing publications Michael Charlton has written about End Stage Liver Disease.
Connection Strength
3.545
-
International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation. 2018 05; 102(5):727-743.
Score: 0.600
-
Predictors of Cardiovascular Events After Liver Transplantation. Clin Liver Dis. 2017 05; 21(2):367-379.
Score: 0.553
-
Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017 04; 152(5):1090-1099.e1.
Score: 0.549
-
Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events. Liver Transpl. 2014 Jul; 20(7):791-7.
Score: 0.457
-
The lethal and enduring inequity of deceased donor liver allocation policy for hepatocellular carcinoma in the United States. Am J Transplant. 2013 Nov; 13(11):2794-6.
Score: 0.437
-
Liver Transplantation 2023: Status Report, Current and Future Challenges. Clin Gastroenterol Hepatol. 2023 07; 21(8):2150-2166.
Score: 0.212
-
Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era. Liver Transpl. 2019 04; 25(4):598-609.
Score: 0.160
-
Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018 06; 154(8):2111-2121.e8.
Score: 0.149
-
International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. Transplantation. 2017 05; 101(5):945-955.
Score: 0.140
-
International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. Transplantation. 2017 05; 101(5):956-967.
Score: 0.140
-
Obesity is independently associated with infection in hospitalised patients with end-stage liver disease. Aliment Pharmacol Ther. 2015 Dec; 42(11-12):1271-80.
Score: 0.126
-
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 2011 May; 17(5):528-38.
Score: 0.023